Teriflunomide — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

2 Recruiting

6 Completed trials

6 Sponsors

25 Countries

Phase III

Phase II

Phase III: 9 Phase II: 1

Indications tested

Secondary progressive multiple sclerosis 4 Relapsing multiple sclerosis 4 Multiple sclerosis 2 Progressive relapsing multiple sclerosis 2 Progressive multiple sclerosis 1 Primary progressive multiple sclerosis 1 Relapsing-remitting multiple sclerosis 1 Multiple sclerosis relapse 1

Sponsors using this IMP

Novartis Pharma AG 3 Centre Hospitalier Universitaire De Nantes 2 Sanofi-Aventis Recherche & Developpement 2 Antwerp University Hospital 1 Les Hopitaux Universitaires De Strasbourg 1 Sanofi-Aventis Research & Development 1

All trials

10 total

A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Not authorised

2023-503631-18-00 Phase III 2 countries Sanofi-Aventis Research & Development
DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending

2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting

2024-513475-41-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Phase III 23 countries Sanofi-Aventis Recherche & Developpement
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended

2024-514343-29-00 Phase III 16 countries Sanofi-Aventis Recherche & Developpement
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country Antwerp University Hospital
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Phase III 13 countries Novartis Pharma AG
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Phase III 15 countries Novartis Pharma AG
STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended

2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 Phase III 4 countries Novartis Pharma AG

Showing 1–10 of 10 trials

← All drugs A–Z